CA2844671A1 - Biomarker compositions and methods - Google Patents

Biomarker compositions and methods Download PDF

Info

Publication number
CA2844671A1
CA2844671A1 CA2844671A CA2844671A CA2844671A1 CA 2844671 A1 CA2844671 A1 CA 2844671A1 CA 2844671 A CA2844671 A CA 2844671A CA 2844671 A CA2844671 A CA 2844671A CA 2844671 A1 CA2844671 A1 CA 2844671A1
Authority
CA
Canada
Prior art keywords
mir
cancer
epcam
pcsa
mmp7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2844671A
Other languages
English (en)
French (fr)
Inventor
Kirk Brown
Traci Pawlowski
David Spetzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caris Life Sciences Switzerland Holdings GmbH
Original Assignee
Caris Life Sciences Luxembourg Holdings SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris Life Sciences Luxembourg Holdings SARL filed Critical Caris Life Sciences Luxembourg Holdings SARL
Publication of CA2844671A1 publication Critical patent/CA2844671A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
CA2844671A 2011-08-08 2012-08-08 Biomarker compositions and methods Abandoned CA2844671A1 (en)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US201161521333P 2011-08-08 2011-08-08
US61/521,333 2011-08-08
US201161523763P 2011-08-15 2011-08-15
US61/523,763 2011-08-15
US201161526623P 2011-08-23 2011-08-23
US61/526,623 2011-08-23
US201161529762P 2011-08-31 2011-08-31
US61/529,762 2011-08-31
US201161534352P 2011-09-13 2011-09-13
US61/534,352 2011-09-13
US201161537462P 2011-09-21 2011-09-21
US61/537,462 2011-09-21
US201161542639P 2011-10-03 2011-10-03
US61/542,639 2011-10-03
US201161551674P 2011-10-26 2011-10-26
US61/551,674 2011-10-26
US201161559676P 2011-11-14 2011-11-14
US61/559,676 2011-11-14
US201261612111P 2012-03-16 2012-03-16
US61/612,111 2012-03-16
US201261619803P 2012-04-03 2012-04-03
US61/619,803 2012-04-03
PCT/US2012/050030 WO2013022995A2 (en) 2011-08-08 2012-08-08 Biomarker compositions and methods

Publications (1)

Publication Number Publication Date
CA2844671A1 true CA2844671A1 (en) 2013-02-14

Family

ID=47669214

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2844671A Abandoned CA2844671A1 (en) 2011-08-08 2012-08-08 Biomarker compositions and methods

Country Status (8)

Country Link
EP (1) EP2742154A4 (ja)
JP (1) JP2014522993A (ja)
KR (1) KR20140067001A (ja)
CN (1) CN103874770A (ja)
AU (1) AU2012294458A1 (ja)
BR (1) BR112014002975A2 (ja)
CA (1) CA2844671A1 (ja)
WO (1) WO2013022995A2 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023169686A1 (en) * 2022-03-10 2023-09-14 Buzzard Pharmaceuticals AB Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294216A4 (en) 2008-05-14 2011-11-23 Dermtech Int DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
NZ703411A (en) 2012-06-27 2017-09-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
CN103160509B (zh) * 2013-03-07 2015-02-18 新乡医学院第一附属医院 一种与食管癌术后早期复发和预后相关的miRNA标志物及其应用
AU2014239309B2 (en) * 2013-03-15 2020-03-05 Beth Israel Deaconess Medical Center, Inc. miRNA biogenesis in exosomes for diagnosis and therapy
CN104076151B (zh) * 2013-03-29 2017-04-12 复旦大学附属华山医院 一种用于胶质瘤早期诊断的试剂盒
WO2014177576A1 (en) * 2013-04-29 2014-11-06 Apogenix Gmbh Method of diagnosing cancer
US10570455B2 (en) 2013-05-10 2020-02-25 University Of Southern California DNA methylation biomarkers for bladder cancer
RU2668164C2 (ru) * 2013-08-06 2018-09-26 Эксосам Дайэгностикс, Инк. Когорты биомаркеров мочи, профиль экспрессии генов и способы их применения
DK3039424T3 (da) * 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
EP3039174B1 (en) * 2013-08-28 2019-10-16 Caris Science, Inc. Oligonucleotide probes and uses thereof
JP6255035B2 (ja) * 2013-11-06 2017-12-27 Jsr株式会社 分離方法、検出方法、シグナル測定方法、疾患の判定方法、疾患治療薬の薬効評価方法、キット及び液状組成物
FR3014198B1 (fr) * 2013-12-03 2017-03-03 Biomerieux Sa Procede d'isolement d'exosomes
EP3078889B1 (en) * 2013-12-06 2019-09-18 The University of Tokyo Valve, fluid-controlling structure, fluid device, and method for manufacturing valve
JP2017509351A (ja) * 2013-12-30 2017-04-06 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 前立腺癌遺伝子プロファイル及びその使用方法
JP2017503169A (ja) 2013-12-31 2017-01-26 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
US20170051359A1 (en) * 2014-05-01 2017-02-23 Stichting Vumc SMALL ncRNAS AS BIOMARKERS
ES2481819B1 (es) * 2014-06-12 2015-04-01 Sistemas Genómicos, S.L. Método de evaluación para evaluar una posibilidad de cáncer de mama
CA2951016A1 (en) 2014-06-12 2015-12-17 Toray Industries, Inc. Prostate cancer detection kit or device, and detection method
US20160038608A1 (en) * 2014-08-07 2016-02-11 National Taiwan University Silica-based mesoporous carrier and delivery method of using the same
KR102328327B1 (ko) * 2014-09-26 2021-11-22 소마로직, 인크. 심혈관 위험 사건 예측 및 이의 용도
KR101596166B1 (ko) 2014-10-07 2016-02-19 가톨릭대학교 산학협력단 유방암 진단 및 치료를 위한 마이크로 ｒｎａ의 용도
CN104313171A (zh) * 2014-11-06 2015-01-28 南京大学 一种诊断神经胶质瘤的microRNA分子标记物及其应用
AU2015360694B2 (en) * 2014-12-08 2021-10-14 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN105807063B (zh) * 2014-12-29 2018-02-06 中国人民解放军第二军医大学 Cd63在制备肝脏疾病诊断试剂盒或制备预防或治疗肝脏疾病药物中的应用
CN104548134A (zh) * 2015-01-04 2015-04-29 中国人民解放军第二军医大学 miR-144及其抑制剂的应用
WO2016112031A1 (en) * 2015-01-05 2016-07-14 The Johns Hopkins University Method of epigenetic analysis for determining clinical genetic risk
WO2016121821A1 (ja) * 2015-01-27 2016-08-04 Jsr株式会社 分離方法、検出方法、シグナル測定方法、疾患の判定方法、薬効評価方法、キット、液状組成物及び検体希釈液
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2017141243A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN107533058A (zh) 2015-03-01 2018-01-02 免疫阵列有限公司 使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮
US20180066262A1 (en) 2015-03-09 2018-03-08 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN104714032B (zh) * 2015-04-02 2015-09-16 闫星宇 用于产后子痫诊断的标志物及其检测试剂
CN113106053A (zh) 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
WO2016186215A1 (ja) * 2015-05-20 2016-11-24 Jsr株式会社 分離方法、検出方法、シグナル測定方法、疾患の判定方法、薬効評価方法、キット、液状組成物及び検体希釈液
JP2018520125A (ja) 2015-06-10 2018-07-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患の処置のためのエキソソームの使用
CN104992058B (zh) * 2015-06-25 2017-08-01 成都厚立信息技术有限公司 疾病风险调整模型建立方法
EP3314027A4 (en) 2015-06-29 2019-07-03 Caris Science, Inc. THERAPEUTIC OLIGONUCLEOTIDES
CN105177117A (zh) * 2015-07-03 2015-12-23 张理义 重症抑郁障碍生物标记物、筛选方法及试剂盒
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用
AU2016298317B2 (en) 2015-07-28 2021-02-18 Caris Science, Inc. Targeted oligonucleotides
CN105039342B (zh) * 2015-08-06 2017-12-01 李家平 能抑制MAT2A基因表达的siRNA及其应用
WO2017025954A1 (en) * 2015-08-09 2017-02-16 Immunarray Ltd Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes
CN105067822B (zh) * 2015-08-12 2017-05-24 中山大学附属肿瘤医院 用于食管癌诊断的标志物
JP6583817B2 (ja) * 2015-09-04 2019-10-02 国立大学法人山口大学 子宮平滑筋における腫瘍の診断マーカー
CN108026584B (zh) * 2015-09-11 2021-12-10 适体科学株式会社 非小细胞肺癌诊断用蛋白质生物标志物组及利用其的非小细胞肺癌诊断方法
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
EP3165926A1 (en) * 2015-11-06 2017-05-10 Humanitas Mirasole S.p.A. Method for characterization of cell specific microvesicles
WO2017112921A1 (en) * 2015-12-24 2017-06-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing sepsis
WO2017113565A1 (zh) * 2015-12-29 2017-07-06 中国医学科学院肿瘤医院 基于蛋白标志物psg3辅助诊断肝癌或消化道癌症患者的试剂盒
CN109715802A (zh) 2016-03-18 2019-05-03 卡里斯科学公司 寡核苷酸探针及其用途
CN105842461A (zh) * 2016-04-30 2016-08-10 广州恒泰生物科技有限公司 子宫肉瘤早中期快速诊断试剂盒及其制备方法
US11293017B2 (en) 2016-05-25 2022-04-05 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN107475356A (zh) * 2016-06-08 2017-12-15 益善生物技术股份有限公司 骨肉瘤循环肿瘤细胞鉴定试剂盒
CN105907875A (zh) * 2016-06-13 2016-08-31 武汉泰安康生物科技有限公司 一种筛选肾癌外周血miRNA标志物的方法及肾癌标志物miR-378
JP6980219B2 (ja) * 2016-08-22 2021-12-15 いであ株式会社 がんを検出、又はがんの進行期を判定する方法
WO2018091419A1 (en) * 2016-11-15 2018-05-24 Ventana Medical Systems, Inc. Compositions and methods for prognosing and treating colorectal cancer
CN108165635B (zh) * 2016-12-07 2021-07-13 南京农业大学 Kiaa1462基因启动子区变异位点及其在提高鹅产蛋性能上的应用
US20210072255A1 (en) 2016-12-16 2021-03-11 The Brigham And Women's Hospital, Inc. System and method for protein corona sensor array for early detection of diseases
EP3554681B1 (en) * 2016-12-16 2022-02-02 The Brigham and Women's Hospital, Inc. Method for protein corona sensor array for early detection of diseases
CN106636296A (zh) * 2016-12-22 2017-05-10 广州医科大学附属肿瘤医院 Hsp27在舌癌化疗耐受诊治中的应用
CN106501517B (zh) * 2016-12-27 2018-05-08 北京蛋白质组研究中心 检测血清中sparc蛋白的物质在制备筛查肝细胞癌试剂盒中的应用
CN106939340A (zh) * 2017-03-31 2017-07-11 哈尔滨医科大学 一种与肺腺癌转移及预后相关的分子标记物及其应用
CN106947820B (zh) * 2017-04-11 2020-09-29 成都望路医药技术有限公司 Vcan在结肠腺癌诊治中的用途
CN111742370A (zh) 2017-05-12 2020-10-02 密歇根大学董事会 个体和队列药理学表型预测平台
CN106987649A (zh) * 2017-05-31 2017-07-28 上海博慷生物科技有限公司 一种用于检测脑胶质瘤的引物组及检测方法
CN109085355A (zh) * 2017-06-13 2018-12-25 中国医学科学院肿瘤医院 血清蛋白标志物组合在肺癌筛查和诊治中的应用
CN107273718A (zh) * 2017-06-27 2017-10-20 电子科技大学 一种融合dna甲基化特征的生存时间分析方法
JP7029719B2 (ja) * 2017-08-31 2022-03-04 静岡県 バイオマーカー
CN107630092B (zh) * 2017-10-23 2020-03-31 广州医科大学附属第二医院 miR-505-3p应用于前列腺癌骨转移的诊断、预后和治疗
US11971414B2 (en) * 2017-12-22 2024-04-30 Wisconsin Alumni Research Foundation Nanoengineered surfaces for cancer biomarker capture
CN107868829B (zh) * 2017-12-26 2021-05-18 浙江自贸区锐赛生物医药科技有限公司 评估脊索瘤术后复发风险的组合试剂、试剂盒及其应用
CN107937621A (zh) * 2018-01-12 2018-04-20 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） miRNA的应用、应用其的产品及检测方法
CN108192970A (zh) * 2018-01-24 2018-06-22 苏州大学 一种肝癌诊断标志物及其应用
CN108048460B (zh) * 2018-02-01 2021-04-09 浙江大学 一种新型分子标记及其在制备用于头颈癌诊断和预后的试剂盒中的应用
CA3090785A1 (en) 2018-02-14 2019-08-22 John Daniel Dobak Iii Novel gene classifiers and uses thereof in non-melanoma skin cancers
SG11202009696WA (en) * 2018-04-13 2020-10-29 Freenome Holdings Inc Machine learning implementation for multi-analyte assay of biological samples
FR3080185A1 (fr) * 2018-04-16 2019-10-18 Biomerieux Evaluation du risque de complication chez un patient suspecte d'avoir une infection ayant un score sofa inferieur a deux
CN108559778B (zh) * 2018-04-28 2020-06-12 北京师范大学 多发性骨髓瘤分子分型及其在用药指导上的应用
CN108570501B (zh) * 2018-04-28 2020-06-12 北京师范大学 多发性骨髓瘤分子分型及应用
CN108586579B (zh) * 2018-05-11 2021-11-30 京东方科技集团股份有限公司 一种类肽及其衍生物、盐、制备方法和用途
CN113855675A (zh) * 2018-05-22 2021-12-31 郑州大学第一附属医院 基于胆囊癌标志物的试剂盒及药物
CN108841962B (zh) * 2018-08-01 2021-11-19 博奥生物集团有限公司 一种非小细胞肺癌检测试剂盒及其应用
KR102094608B1 (ko) * 2018-08-08 2020-04-23 고려대학교 산학협력단 혈액암의 분류 및 예후 판단에 필요한 정보를 제공하는 방법
WO2020032228A1 (ja) 2018-08-10 2020-02-13 東レ株式会社 前立腺がんの検出のためのキット、デバイス及び方法
CN109321656B (zh) * 2018-10-22 2021-10-01 上海交通大学医学院附属仁济医院 蛋白depdc1作为诊断三阴乳腺癌的标记物的用途
KR20210068545A (ko) * 2018-11-01 2021-06-09 카오카부시키가이샤 피험체의 피부 세포에서 유래하는 핵산의 조제 방법
CN109507425A (zh) * 2018-11-07 2019-03-22 国家纳米科学中心 基于热泳细胞外囊泡的前列腺癌症复发监控系统及方法
KR102594366B1 (ko) 2018-11-07 2023-10-27 시어 인코퍼레이티드 단백질 코로나 분석을 위한 조성물, 방법 및 시스템 및 그것들의 용도
WO2020104588A1 (en) * 2018-11-22 2020-05-28 Institut D'investigació Sanitària Pere Virgili Biomarkers of prostate cancer aggressiveness
CN109609630B (zh) * 2018-12-03 2023-01-13 哈尔滨医科大学 用于早期胃癌诊断的分子标志物及其应用
CN109439757A (zh) * 2018-12-18 2019-03-08 首都医科大学附属北京佑安医院 血浆外泌体miR-455-3p作为早期肝癌诊断标志物的应用
CN109652504B (zh) * 2018-12-27 2021-03-16 杭州迪相实业有限公司 一种同时检测外泌体膜蛋白和mRNA的方法
US20220088016A1 (en) * 2019-01-02 2022-03-24 Zhejiang Crownmab Biotech Co. Ltd. Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers
CN109609653B (zh) * 2019-02-12 2019-07-19 山东大学齐鲁医院 诊断或治疗胶质瘤的分子标记物及其应用
EP3699300A1 (en) * 2019-02-22 2020-08-26 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Seminal mirnas as non-invasive biomarkers for the diagnosis and/or prognosis of prostate cancer
CA3134936A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
CN110196329A (zh) * 2019-05-31 2019-09-03 郑州大学第一附属医院 一种食管癌早期联合检测试剂盒
JPWO2020262374A1 (ja) * 2019-06-27 2020-12-30
CN110279707A (zh) * 2019-07-05 2019-09-27 深圳市康宁医院(深圳市精神卫生研究所深圳市精神卫生中心) miR-212在制备用于治疗成瘾的药物中的应用
WO2021013479A1 (en) * 2019-07-19 2021-01-28 Universiteit Antwerpen Mucin isoforms in diseases characterized by barrier dysfunction
KR102346864B1 (ko) * 2019-07-24 2022-01-04 한국전자기술연구원 방광암 진단 또는 예후 분석용 바이오마커 조성물, 키트 및 이를 이용한 진단 방법
CN117169534A (zh) 2019-08-05 2023-12-05 禧尔公司 用于样品制备、数据生成和蛋白质冠分析的系统和方法
CN110295228A (zh) * 2019-08-05 2019-10-01 中国人民解放军总医院第八医学中心 检测gata2的物质在制备诊断活动性结核病的试剂盒中的应用
CN110551809A (zh) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 miR-124在脊髓损伤修复中的用途
CN110564867B (zh) * 2019-10-10 2022-06-24 扬州大学 一种秦川牛cfl1基因的snp分子标记及其检测方法
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
WO2021132654A1 (ja) * 2019-12-27 2021-07-01 関西ペイント株式会社 塗料の製造方法、色彩データを予測する方法及びコンピュータ調色システム
CN111647658B (zh) * 2020-06-05 2022-09-27 上海市第一人民医院 Linc00963相关致癌轴在前列腺癌远处转移的早期诊断和治疗中的应用
CN111690746A (zh) * 2020-06-30 2020-09-22 镇江维思生物科技有限责任公司 与肺癌相关的血小板rna标志物及其应用
CN113940999B (zh) * 2020-07-15 2022-11-29 中国农业大学 一种治疗非酒精性脂肪肝性肝病治疗靶点的应用
CN112180100A (zh) * 2020-09-27 2021-01-05 西安交通大学 Tweak作为鉴别不同类型银屑病的分子标志物的应用
CN112255408B (zh) * 2020-10-16 2023-04-14 牡丹江医学院 一种肿瘤生物标志物及肿瘤检测试剂盒
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
CN112433053A (zh) * 2020-11-20 2021-03-02 四川大学华西医院 Tetraspanin-14蛋白检测试剂在制备肺癌筛查试剂盒中的用途
CN112301133B (zh) * 2020-12-01 2021-07-27 江门市中心医院 胆固醇生成基因标签在年轻乳腺癌患者预后预测中的应用
KR102427057B1 (ko) * 2020-12-04 2022-07-29 전남대학교산학협력단 단일섬유종양/혈관주위세포종 전이 진단 또는 예후 분석용 바이오 마커 및 이를 이용한 진단방법
US20240052422A1 (en) 2020-12-24 2024-02-15 Pontificia Universidad Catolica De Chile In-vitro method for diagnosing and predicting the aggressiveness of thyroid cancer, and the precision surgery options and type to be used to remove a tumour from a patient; kit; reagents forming the kit; and use of the reagents and use of molecular markers as part of the method
CN113151460B (zh) * 2021-01-29 2022-10-18 复旦大学附属中山医院 一种识别肺腺癌肿瘤细胞的基因标志物及其应用
CN115166245A (zh) * 2021-04-04 2022-10-11 兰州大学第一医院 Clu及其组合物在诊断胆管癌中的应用及胆管癌诊断试剂盒
KR102540416B1 (ko) * 2021-04-09 2023-06-12 주식회사 애티스랩 암 진단용 조성물, 키트, 및 이를 이용한 암 진단 방법
CN113125757B (zh) * 2021-04-22 2022-10-28 石河子大学 一种用于母猪早期妊娠诊断的蛋白生物标志物及其用于母猪早期妊娠检测的方法
CN113122544A (zh) * 2021-04-25 2021-07-16 杭州广科安德生物科技有限公司 一种特异性结合timp1蛋白的核酸适配体及其应用
CN113311166B (zh) * 2021-04-28 2022-10-28 新疆农垦科学院 一种用于绵羊早期妊娠诊断的蛋白生物标志物及其用于绵羊早期妊娠检测的方法
CN113186267A (zh) * 2021-06-07 2021-07-30 上海康黎诊断技术有限公司 一种人cyp2d6拷贝数变异和基因分型检测的引物探针组合、试剂盒以及方法
CN113687076B (zh) * 2021-07-14 2024-03-01 郑州大学 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用
GB202111635D0 (en) * 2021-08-13 2021-09-29 Randox Laboratories Risk prediction model for prostate cancer
WO2023054436A1 (ja) * 2021-09-29 2023-04-06 株式会社西尾 美容方法
WO2023064883A1 (en) * 2021-10-14 2023-04-20 The University Of Chicago Immunotherapeutic methods for treating cancer
WO2023140658A1 (ko) * 2022-01-24 2023-07-27 고려대학교 산학협력단 뇌유래신경성장인자를 이용한 패혈증 진단, 예방 또는 치료용 약학적 조성물
WO2024050856A1 (zh) * 2022-09-06 2024-03-14 南京市第一医院 一种辅助血细胞分析仪判定异常血小板聚集的方法和系统
WO2024091020A1 (ko) * 2022-10-26 2024-05-02 연세대학교 산학협력단 유방암 진단 또는 재발 예측을 위한 세포외 소포체 유래 miRNA 유전자 바이오마커 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
WO2005042725A2 (en) * 2003-11-03 2005-05-12 Genenews, Inc. Liver cancer biomarkers
EP1904645B1 (en) * 2005-07-08 2010-08-04 Siemens Healthcare Diagnostics GmbH Method for predicting and monitoring direct response to cancer therapy
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2008069881A2 (en) * 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
BRPI0806436A2 (pt) * 2007-01-26 2011-09-06 Univ Lousville Res Foundation Inc modificação de componentes exossomais para uso como uma vacina
US8216784B2 (en) * 2007-07-25 2012-07-10 University Of Louisville Research Foundation, Inc. Cancer-derived microvesicle-associated microrna as a diagnostic marker
US8728823B2 (en) * 2007-11-23 2014-05-20 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
WO2009147519A1 (en) * 2008-06-06 2009-12-10 Centre National De La Recherche Scientifique - Cnrs- Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna
CA2742324A1 (en) * 2008-10-30 2010-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods for assessing rna patterns
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
US20130029339A1 (en) * 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
WO2011066589A1 (en) * 2009-11-30 2011-06-03 Caris Life Sciences Luxembourg Holdings Methods and systems for isolating, storing, and analyzing vesicles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023169686A1 (en) * 2022-03-10 2023-09-14 Buzzard Pharmaceuticals AB Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer

Also Published As

Publication number Publication date
JP2014522993A (ja) 2014-09-08
EP2742154A2 (en) 2014-06-18
BR112014002975A2 (pt) 2017-03-01
AU2012294458A1 (en) 2014-02-27
EP2742154A4 (en) 2015-08-12
KR20140067001A (ko) 2014-06-03
CN103874770A (zh) 2014-06-18
WO2013022995A2 (en) 2013-02-14
WO2013022995A3 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
US20140228233A1 (en) Circulating biomarkers for cancer
CA2844671A1 (en) Biomarker compositions and methods
US20160041153A1 (en) Biomarker compositions and markers
US20140220580A1 (en) Biomarker compositions and methods
AU2011237669B2 (en) Circulating biomarkers for disease
US20150152474A1 (en) Biomarker compositions and methods
AU2011291599B2 (en) Circulating biomarkers for disease
US20150301058A1 (en) Biomarker compositions and methods
US20140141986A1 (en) Circulating biomarkers
WO2014193999A2 (en) Biomarker methods and compositions

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180808